Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

79.00 -1.98 (-2.45%)
Official Closing Price Updated: 7:00 PM EDT, Mar 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
70 71 Next >
Is This Simple Index Fund a Millionaire Maker?
Wondering if you should look beyond American markets to build your fortune? This widely held international fund offers a few opportunities and several challenges. 
Via The Motley Fool
Is Novo Nordisk a No-Brainer Buy After It Dropped 40%?
Via The Motley Fool
Why Novo Nordisk Stock Outpaced the Market on Tuesday
Via The Motley Fool
Is Viking Therapeutics the Next Blockbuster GLP-1 Stock?
Viking Therapeutic may have a GLP-1 blockbuster on their hands with VK2735 as it produces weight loss at 5X the speed of Novo Nordisk's Wegovy GLP-1 drug. 
Via MarketBeat
Why Novo Nordisk Stock Is Falling Today
Via The Motley Fool
UK Pharma Industry Trade Association Restores Wegovy/Ozempic Maker Novo Nordisk's Membership After 2 Years Of Suspension
Novo Nordisk rejoined the ABPI after a two-year suspension linked to promotional concerns. Audits confirmed compliance with industry standards. 
Via Benzinga
Why Hims & Hers Stock Popped on Monday
Morgan Stanley had great news for Hims & Hers stock today, so why didn't it upgrade the stock? 
Via The Motley Fool
3 Unstoppable Stocks You Can Buy Now Without Any Hesitation
Via The Motley Fool
CVS Weight Management Program Yields 15% Average Weight Loss, 26% Cost Saving Among Participants
CVS Weight Management program members achieved 15% average weight loss, with 92% satisfaction and 26% lower GLP-1 medication costs for participating clients. 
Via Benzinga
Altimmune Expands Weight-Loss Drug Pemvidutide's Potential To Alcohol-Related Disorders
Altimmune plans Phase 2 trials in 2025 for pemvidutide in alcohol use disorder and liver disease, highlighting weight loss and liver health benefits. 
Via Benzinga
The Motley Fool's Market Volatility Toolkit
Long-Term Perspective and Practical Steps for Uncertain Times 
Via The Motley Fool
EXCLUSIVE: Vivani Medical Announces First Implant In Early-Stage Human Study Of GLP-1 Implant For Obesity
Vivani Medical completed enrollment in its LIBERATE-1 trial, testing a six-month GLP-1 implant for weight management. Top-line results are expected by mid-2025. 
Via Benzinga
Why Viking Therapeutics and Roche Holdings Popped Today, but Novo Nordisk Stock Dropped
Ignore the noise in GLP-1 stocks. Find the best value instead. 
Via The Motley Fool
Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion
The company is looking to test a combination of the drug it acquired from Carmot Therapeutics and a amylin-based drug. 
Via Investor's Business Daily
Why Hims & Hers Health Stock Just Popped
Via The Motley Fool
Top 3 Health Care Stocks That May Keep You Up At Night In Q1
Via Benzinga
Novo Nordisk's Combo Drug CagriSema Shows 16% Weight Reduction In Second Phase 3 Trial
Novo Nordisk's REDEFINE 2 trial shows CagriSema led to significant weight loss in patients with obesity and type 2 diabetes. Regulatory filing is planned for 2026. 
Via Benzinga
These 2 Vanguard ETFs Are Crushing the S&P 500 in 2025. Should You Buy?
Via The Motley Fool
Topics ETFs Stocks
Exposures US Equities
Hims & Hers Stock Is Down 50% From Its High, but Is This a Buying Opportunity?
Shutting down an acquisition caught investor attention, but there's more to the story. 
Via The Motley Fool
Is Eli Lilly Stock a Buy?
Via The Motley Fool
The State of Weight Loss Drugs
Via The Motley Fool
Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors
Novo Nordisk slashed prices on its GLP-1 obesity drugs as it launches NovoCare to gain compounded GLP-1 users as the compounding labs face deadlines to cease. 
Via MarketBeat
Exposures Product Safety
3 Cold Stocks That Can Bounce Back This Week
These three stocks tumbled by at least 20% last week, but they may not be down for long. 
Via The Motley Fool
Novo Nordisk Dives 8%. Why Eli Lilly Now Has The Upper Hand.
Novo Nordisk's experimental obesity drug failed to top Eli Lilly's Zepbound. But there's something else that rattled investors. 
Via Investor's Business Daily
Rocket Companies, Novo Nordisk And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Weight Loss Drugs Soar While Global Obesity Rates Climb, To Hit 50% Of Adults By 2050 Says New Report
A global study shows obesity rates predicted to climb. Are weight loss drugs not doing enough or not available in enough countries? 
Via Benzinga
Amgen Challenges Novo Nordisk's Ozempic And Eli Lilly's Zepbound As Its Monthly Weight Loss Drug MariTide Enters Two Late-Stage Trials
Via Benzinga
Why Novo Nordisk Stock Outpaced the Market Today and Hims & Hers Lagged It
Via The Motley Fool
Why Is Hims & Hers Health Stock Trading Lower On Wednesday?
Hims & Hers Health stock drops over 20% after the FDA removes semaglutide from the shortage list. Novo Nordisk launches a direct delivery service for Wegovy. 
Via Benzinga
Exposures Product Safety
Novo Nordisk Boosts Wegovy Access With Lower Pricing and Home Delivery
Novo Nordisk launches NovoCare Pharmacy, offering uninsured and cash-paying patients Wegovy for $499 per month. The service includes home delivery, live support, and safeguards against compounded... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
70 71 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback